Parameswaran Nair

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2893983/publications.pdf

Version: 2024-02-01

193 papers	12,152 citations	44069 48 h-index	27406 106 g-index
200 all docs	200 docs citations	200 times ranked	9067 citing authors

#	Article	IF	Citations
1	Clinical relevance of sputum bronchial epithelial cells: A retrospective cross-sectional study. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 35-40.	0.5	0
2	Iron in airway macrophages and infective exacerbations of chronic obstructive pulmonary disease. Respiratory Research, 2022, 23, 8.	3.6	13
3	Eosinophils as potential mediators of autoimmunity in eosinophilic lung disease. , 2022, , 219-237.		4
4	EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1667-1684.	5.7	12
5	Standardized Cannabis Smoke Extract Induces Inflammation in Human Lung Fibroblasts. Frontiers in Pharmacology, 2022, 13, 852029.	3.5	3
6	Impact of former smoking exposure on airway eosinophilic activation and autoimmunity in patients with severe asthma. European Respiratory Journal, 2022, 60, 2102446.	6.7	15
7	Persistent Airway Plugs: A Call for Clinical Recognition and Novel Therapies. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	5
8	Asthma Control, Airway Mucus, and 129Xe MRI Ventilation After a Single Benralizumab Dose. Chest, 2022, 162, 520-533.	0.8	25
9	Benralizumab's anti-eosinophil efficacy may be decreased by impaired NK cell activity. European Respiratory Journal, 2022, 59, 2102210.	6.7	3
10	Role of Human Antigen R (HuR) in the Regulation of Pulmonary ACE2 Expression. Cells, 2022, 11, 22.	4.1	6
11	Disease-modifying anti-asthmatic drugs. Lancet, The, 2022, 399, 1664-1668.	13.7	42
12	The Inability to Limit Autoimmune Pathology Is Associated with COVID-19 Hospital Fatality. , 2022, , .		0
13	Abnormal ¹²⁹Xe Ventilation MRI and Inhaled Corticosteroid Deposition in Severe Asthma. , 2022, , .		0
14	Hyperpolarized ¹²⁹Xe Magnetic Resonance Imaging for the Assessment of Bronchiolitis Obliterans Syndrome (BOS) and Other Late-Onset Non-Infectious Pulmonary Complications (LONIPCs) Following Hematopoietic Stem Cell Transplantation. , 2022, , .		0
15	Eosinophil-Independent IL-5 Increase in Critically Ill COVID-19 Patients Associates with Favourable Outcome. , 2022, , .		0
16	A 68-Year-Old Woman With Refractory Cough and Insidious Tracheal Thickening. Chest, 2022, 161, e287-e291.	0.8	0
17	Airway Inflammatory Endotypes and Magnetic Resonance Imaging Ventilation Heterogeneity in Severe Asthma. , 2022, , .		0
18	Prevalence and Clinical Relevance of Ventilation Heterogeneity and Luminal Cellular Inflammation in Lung Cancer Patients Prior to Lung Resection: An Interim Analysis. , 2022, , .		0

#	Article	IF	Citations
19	CFTR heterozygosity in severe asthma with recurrent airway infections: a retrospective review. Allergy, Asthma and Clinical Immunology, 2022, 18, .	2.0	2
20	EAACI Biologicals Guidelinesâ€"Recommendations for severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 14-44.	5.7	156
21	Dupilumab, severe asthma airway responses, and SARSâ€CoVâ€2 serology. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 957-958.	5.7	26
22	Asthma exacerbations on benralizumab are largely nonâ€eosinophilic. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 375-379.	5.7	36
23	Benralizumab for Prednisone-Dependent Eosinophilic Asthma Associated With Novel STAT3 Loss of Function Mutation. Chest, 2021, 159, e181-e184.	0.8	6
24	Monitoring eosinophils to guide therapy with biologics in asthma: does the compartment matter?. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1294-1297.	5.7	13
25	Angiotensin-converting enzyme 2 expression in COPD and IPF fibroblasts: the forgotten cell in COVID-19. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L152-L157.	2.9	20
26	The role of eosinophils in sepsis and acute respiratory distress syndrome: a scoping review. Canadian Journal of Anaesthesia, 2021, 68, 715-726.	1.6	18
27	There is more to severe asthma associated with obesity than inflammation. Respirology, 2021, 26, 288-289.	2.3	2
28	Aryl hydrocarbon receptor deficiency causes the development of chronic obstructive pulmonary disease through the integration of multiple pathogenic mechanisms. FASEB Journal, 2021, 35, e21376.	0.5	15
29	Human antigen R promotes lung fibroblast differentiation to myofibroblasts and increases extracellular matrix production. Journal of Cellular Physiology, 2021, 236, 6836-6851.	4.1	17
30	Inspiratory and Expiratory Respiratory System Resistance in Severe Asthma Pre- and Post-Bronchodilator. , 2021, , .		0
31	Neutrophilic asthma: misconception or misnomer?. Lancet Respiratory Medicine,the, 2021, 9, 441-443.	10.7	35
32	Notch4, uncovering an immunomodulator in allergic asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3852-3854.	5.7	0
33	Medical algorithms: Approach to adult asthma exacerbations. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3556-3559.	5.7	3
34	Differential expression of sputum and serum autoantibodies in patients with chronic obstructive pulmonary disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L1169-L1182.	2.9	4
35	Effect of antiâ€IL‐5 biologics on weight and body mass index. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2913-2916.	5.7	8
36	Underestimation of airway luminal eosinophilia by quantitative sputum cytometry. Allergy, Asthma and Clinical Immunology, 2021, 17, 63.	2.0	12

#	Article	IF	Citations
37	Comprehensive Care Management in Conjunction with Sputum Cytometry-Guided Pharmacotherapy in a Post-Discharge Clinic for Patients with COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 411-416.	1.6	0
38	Detecting immunoglobulins in processed sputa. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3798-3800.	5.7	3
39	Pan-Canadian standards for severe asthma in electronic medical records. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 391-399.	0.5	2
40	Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma. The Cochrane Library, 2021, 2021, CD012929.	2.8	11
41	Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections. Viruses, 2021, 13, 2239.	3.3	10
42	HuR drives lung fibroblast differentiation but not metabolic reprogramming in response to TGF-Î² and hypoxia. Respiratory Research, 2021, 22, 323.	3.6	6
43	Efficacy of Intravenous Reslizumab in Oral Corticosteroidâ€“Dependent Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 555-564.	3.8	31
44	Mechanisms and therapeutic strategies for nonâ€T2 asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 311-325.	5.7	148
45	Eosinophilic Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 465-473.	3.8	54
46	Is Computed Tomography Airway Count Related to Asthma Severity and Airway Structure and Function?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 923-933.	5.6	46
47	TWIST1 DNA methylation is a cell marker of airway and parenchymal lung fibroblasts that are differentially methylated in asthma. Clinical Epigenetics, 2020, 12, 145.	4.1	9
48	Direct and indirect bronchoprovocation tests in doseâ€response studies of inhaled corticosteroids: Past, present, and future directions. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 76, 1679-1692.	5.7	1
49	Predictors of response to <scp>antiâ€ILâ€5</scp> biologics. Respirology, 2020, 25, 1123-1125.	2.3	3
50	Effects of Anti-T2 Biologic Treatment on Lung Ventilation Evaluated by MRI in Adults With Prednisone-Dependent Asthma. Chest, 2020, 158, 1350-1360.	0.8	24
51	Luminal Eosinophil Cell Death as a Biomarker for Loss of Asthma Control?. Chest, 2020, 157, 1680-1681.	0.8	4
52	Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelinesâ€"Recommendations on the use of biologicals in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1058-1068.	5.7	67
53	Sputum and serum immunoglobulins in adult asthmatics with recurrent respiratory tract infections. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2105-2108.	5.7	6
54	Exon 8 KIT mutation and pulmonary eosinophilia. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2094-2096.	5.7	1

#	Article	IF	Citations
55	Sputum quantitative cytometry in patients with interstitial lung disease and chronic cough. Respiratory Medicine, 2020, 170, 106067.	2.9	2
56	Exacerbations of Severe Asthma While on Antiâ€“IL-5 Biologics. Journal of Investigational Allergology and Clinical Immunology, 2020, 30, 307-316.	1.3	13
57	The Role of the TL1A/DR3 Axis in the Activation of Group 2 Innate Lymphoid Cells in Subjects with Eosinophilic Asthma. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1105-1114.	5.6	35
58	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab) Tj ETQq0 0 0 rgBT /Overlock 10 recommendations on the use of biologicals in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1023-1042.	5.7	232
59	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines â€•recommendations on the use of biologicals in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1043-1057.	5.7	85
60	Reproducibility of Hyperpolarized 129Xe MRI Ventilation Defect Percent in Severe Asthma to Evaluate Clinical Trial Feasibility. Academic Radiology, 2020, 28, 817-826.	2.5	21
61	Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena. European Respiratory Journal, 2020, 56, 2000117.	6.7	71
62	Practical Considerations in the Management of Eosinophilic Asthma. Respiratory Medicine, 2020, , 181-206.	0.1	0
63	Sputum Inflammometry to Manage Chronic Obstructive Pulmonary Disease Exacerbations: Beyond Guidelines. Tuberculosis and Respiratory Diseases, 2020, 83, 175-184.	1.8	2
64	Lessons of the month: A breathless severe asthmatic in the genomic era: Occam's razor or Hickam's dictum?. Clinical Medicine, 2020, 20, e264-e266.	1.9	3
65	Inhaled Corticosteroids and Adult Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1556-1557.	5.6	3
66	Response. Chest, 2019, 156, 808-809.	0.8	0
67	The interleukin-13 paradox in asthma: effective biology, ineffective biologicals. European Respiratory Journal, 2019, 53, 1802250.	6.7	24
68	Reply to Yilmaz: Selection of Biologics for Type 2â€“High Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 791-792.	5.6	1
69	Optimizing sputum cell counts prior to bronchial thermoplasty: A preliminary report. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 143-147.	0.5	7
70	CT and Functional MRI to Evaluate AirwayÂMucus in Severe Asthma. Chest, 2019, 155, 1178-1189.	0.8	77
71	Omalizumab in patients with severe asthma and persistent sputum eosinophilia. Allergy, Asthma and Clinical Immunology, 2019, 15, 21.	2.0	15
72	Eosinophil-derived IL-13 promotes emphysema. European Respiratory Journal, 2019, 53, 1801291.	6.7	47

#	Article	IF	Citations
73	Effect of sex on group 2 innate lymphoid cells in the airways of mild and severe asthmatics. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1397-1400.	5.7	5
74	Normalisation of MRI ventilation heterogeneity in severe asthma by dupilumab. Thorax, 2019, 74, 1087-1088.	5.6	15
75	Rapid quantification of sputum eosinophil peroxidase on a lateral flow test strip. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1176-1178.	5.7	6
76	Much ado about Biologicals: Highlights of the Master Class on Biologicals, Prague, 2018. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 837-840.	5.7	2
77	Role of Biologics in Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 433-445.	5.6	296
78	Clinical biomarkers and noninvasive assessment of severe asthma. , 2019, , 93-112.		2
79	Free-breathing Pulmonary MR Imaging to Quantify Regional Ventilation. Radiology, 2018, 287, 693-704.	7.3	32
80	Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma. Journal of Allergy and Clinical Immunology, 2018, 141, 1529-1532.e8.	2.9	80
81	This is what asthma looks like: Review of new and emerging functional imaging methods and results. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 27-40.	0.5	1
82	Airway Inflammation and Inflammatory Biomarkers. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 056-063.	2.1	25
83	Sputum Eosinophilia and Magnetic Resonance Imaging Ventilation Heterogeneity in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 876-884.	5.6	76
84	Modulation of human airway smooth muscle biology by human adipocytes. Respiratory Research, 2018, 19, 33.	3.6	10
85	Altered DNA methylation is associated with aberrant gene expression in parenchymal but not airway fibroblasts isolated from individuals with COPD. Clinical Epigenetics, 2018, 10, 32.	4.1	31
86	Human Bronchial Epithelial Cellâ€“derived Factors from Severe Asthmatic Subjects Stimulate Eosinophil Differentiation. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 99-106.	2.9	28
87	Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 38-46.	5.6	150
88	Sputum plug selection under inverted microscopy improves microbial identification during exacerbations of airway diseases. Respiratory Medicine, 2018, 134, 92-94.	2.9	2
89	Endogenous peroxidases in sputum interfere with horse-radish peroxidase-based ELISAs. Journal of Immunological Methods, 2018, 454, 76-79.	1.4	8
90	Sputum autoantibodies in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology, 2018, 141, 1269-1279.	2.9	93

#	Article	IF	Citations
91	Airway Eosinophilopoietic and Autoimmune Mechanisms of Eosinophilia in Severe Asthma. Immunology and Allergy Clinics of North America, 2018, 38, 639-654.	1.9	30
92	Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. New England Journal of Medicine, 2018, 378, 2475-2485.	27.0	816
93	Loss of bronchoprotection to Salbutamol during sputum induction with hypertonic saline: implications for asthma therapy. Allergy, Asthma and Clinical Immunology, 2018, 14, 26.	2.0	1
94	Autoimmune Responses in Severe Asthma. Allergy, Asthma and Immunology Research, 2018, 10, 428.	2.9	77
95	Airway Hyperresponsiveness in Asthma: Measurement and Clinical Relevance. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 649-659.e2.	3.8	68
96	Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, S1-S14.	3.8	57
97	Glucocortiosteroid subsensitivity and asthma severity. Current Opinion in Pulmonary Medicine, 2017, 23, 78-88.	2.6	37
98	Oral Glucocorticoidâ€“Sparing Effect of Benralizumab in Severe Asthma. New England Journal of Medicine, 2017, 376, 2448-2458.	27.0	779
99	The use of cellular and molecular biomarkers to manage COPD exacerbations. Expert Review of Respiratory Medicine, 2017, 11, 1-9.	2.5	4
100	A pilot randomised clinical trial ofÂmepolizumab in COPD with eosinophilic bronchitis. European Respiratory Journal, 2017, 49, 1602486.	6.7	51
101	Revisiting <scp>T</scp>ype 2â€high and <scp>T</scp>ype 2â€low airway inflammation in asthma: current knowledge and therapeutic implications. Clinical and Experimental Allergy, 2017, 47, 161-175.	2.9	287
102	Glucocorticoid Sparing of Benralizumab in Asthma. New England Journal of Medicine, 2017, 377, 1204-1205.	27.0	9
103	Improved recovery of functionally active eosinophils and neutrophils using novel immunomagnetic technology. Journal of Immunological Methods, 2017, 449, 44-55.	1.4	29
104	Hemosiderin in sputum macrophages may predict infective exacerbations of chronic obstructive pulmonary disease: a retrospective observational study. BMC Pulmonary Medicine, 2017, 17, 60.	2.0	15
105	Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy. Allergy, Asthma and Clinical Immunology, 2017, 13, 2.	2.0	46
106	Sputum cell counts to manage prednisone-dependent asthma: effects on FEV1 and eosinophilic exacerbations. Allergy, Asthma and Clinical Immunology, 2017, 13, 17.	2.0	18
107	Does the usage of digital chest drainage systems reduce pleural inflammation and volume of pleural effusion following oncologic pulmonary resection?â€”A prospective randomized trial. Journal of Thoracic Disease, 2017, 9, 1598-1606.	1.4	23
108	Asthma Endotypes and an Overview of Targeted Therapy for Asthma. Frontiers in Medicine, 2017, 4, 158.	2.6	190

#	Article	IF	Citations
109	Regulation of human airway smooth muscle cell migration and relevance to asthma. Respiratory Research, 2017, 18, 156.	3.6	68
110	Free-breathing Functional Pulmonary MRI. Academic Radiology, 2017, 24, 1268-1276.	2.5	27
111	Low levels of the AhR in chronic obstructive pulmonary disease (COPD)-derived lung cells increases COX-2 protein by altering mRNA stability. PLoS ONE, 2017, 12, e0180881.	2.5	13
112	Dysregulation of Vascular Endothelial Progenitor Cells Lung-Homing in Subjects with COPD. Canadian Respiratory Journal, 2016, 2016, 1-10.	1.6	13
113	Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisoneâ€dependent severe asthma. Clinical and Experimental Allergy, 2016, 46, 793-802.	2.9	90
114	Histone deacetylase activity and recurrent bacterial bronchitis in severe eosinophilic asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 571-575.	5.7	8
115	Human bronchial and parenchymal fibroblasts display differences in basal inflammatory phenotype and response to ILâ€17A. Clinical and Experimental Allergy, 2016, 46, 945-956.	2.9	15
116	Is ventilation heterogeneity related to asthma control?. European Respiratory Journal, 2016, 48, 370-379.	6.7	62
117	Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine,the, 2016, 4, 797-806.	10.7	202
118	Benralizumab, an anti-interleukin-5 receptor Î± monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, The, 2016, 388, 2128-2141.	13.7	1,070
119	Measuring Eosinophils to Make Treatment Decisions in Asthma. Chest, 2016, 150, 485-487.	0.8	22
120	Eosinophilic Endotype of Asthma. Immunology and Allergy Clinics of North America, 2016, 36, 559-568.	1.9	50
121	Development of a functional point-of-need diagnostic for myeloperoxidase detection to identify neutrophilic bronchitis. Analyst, The, 2016, 141, 6438-6443.	3.5	10
122	Nasal and pharyngeal eosinophil peroxidase levels in adults with poorly controlled asthma correlate with sputum eosinophilia. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 567-570.	5.7	34
123	Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. Journal of Allergy and Clinical Immunology, 2016, 137, 75-86.e8.	2.9	388
124	Fibroblast-epithelial cell interactions drive epithelial-mesenchymal transition differently in cells from normal and COPD patients. Respiratory Research, 2015, 16, 72.	3.6	51
125	A Multidimensional Approach to the Management of Severe Asthma: Inflammometry, Molecular Microbiology and Bronchial Thermoplasty. Canadian Respiratory Journal, 2015, 22, 221-224.	1.6	14
126	Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma. Expert Review of Respiratory Medicine, 2015, 9, 135-142.	2.5	21

#	Article	IF	Citations
127	Decreased expression of the NF-Î²B family member RelB in lung fibroblasts from Smokers with and without COPD potentiates cigarette smoke-induced COX-2 expression. Respiratory Research, 2015, 16, 54.	3.6	25
128	Metabolomic profiling of asthma and chronic obstructive pulmonary disease: AÂpilot study differentiating diseases. Journal of Allergy and Clinical Immunology, 2015, 136, 571-580.e3.	2.9	75
129	Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma. Allergy, Asthma and Clinical Immunology, 2015, 11, 14.	2.0	68
130	A perspective on point-of-care tests to detect eosinophilic bronchitis. Journal of Asthma, 2015, 52, 254-261.	1.7	5
131	Therapeutic implications of â€˜neutrophilic asthmaâ€™. Current Opinion in Pulmonary Medicine, 2015, 21, 33-38.	2.6	39
132	MicroRNA-9 regulates steroid-resistant airway hyperresponsiveness by reducing protein phosphatase 2A activity. Journal of Allergy and Clinical Immunology, 2015, 136, 462-473.	2.9	84
133	The aryl hydrocarbon receptor suppresses cigarette-smoke-induced oxidative stress in association with dioxin response element (DRE)-independent regulation of sulfiredoxin 1. Free Radical Biology and Medicine, 2015, 89, 342-357.	2.9	41
134	Blood or sputum eosinophils to guide asthma therapy?. Lancet Respiratory Medicine,the, 2015, 3, 824-825.	10.7	60
135	Changing Pattern of Sputum Cell Counts During Successive Exacerbations of Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 628-35.	1.6	4
136	The effects of an epithelial barrier protective cationic aerosol on allergenâ€induced airway inflammation in asthma: a randomized, placeboâ€controlled clinical trial. Clinical and Experimental Allergy, 2014, 44, 1200-1203.	2.9	6
137	Safety and efficacy of an oral <scp>CCR</scp>3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placeboâ€controlled clinical trial. Clinical and Experimental Allergy, 2014, 44, 508-516.	2.9	79
138	Anti-IL5 therapy for asthma and beyond. World Allergy Organization Journal, 2014, 7, 32.	3.5	68
139	Upregulation of IL-17A/F from human lung tissue explants with cigarette smoke exposure: implications for COPD. Respiratory Research, 2014, 15, 145.	3.6	31
140	Monoclonal antibodies for the treatment of refractory asthma. Current Opinion in Pulmonary Medicine, 2014, 20, 87-94.	2.6	69
141	Omalizumab for asthma in adults and children. The Cochrane Library, 2014, , CD003559.	2.8	329
142	Antiâ€“Interleukin-5 Monoclonal Antibody to Treat Severe Eosinophilic Asthma. New England Journal of Medicine, 2014, 371, 1249-1251.	27.0	42
143	MicroRNA-155 Is Required for Clearance of Streptococcus pneumoniae from the Nasopharynx. Infection and Immunity, 2014, 82, 4824-4833.	2.2	20
144	Persistence of pulmonary tertiary lymphoid tissues and anti-nuclear antibodies following cessation of cigarette smoke exposure. Respiratory Research, 2014, 15, 49.	3.6	45

#	Article	IF	Citations
145	A halotyrosine antibody that detects increased protein modifications in asthma patients. Journal of Immunological Methods, 2014, 403, 17-25.	1.4	13
146	Relationship between Sputum Eosinophilia and Sinus Disease in Patients with Eosinophilic Bronchitis. American Journal of Rhinology and Allergy, 2014, 28, 378-382.	2.0	1
147	What is an â€œeosinophilic phenotypeâ€•of asthma?. Journal of Allergy and Clinical Immunology, 2013, 132, 81-83.	2.9	66
148	Targeted therapy of bronchitis in obstructive airway diseases. , 2013, 140, 213-222.		22
149	Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma. Respiratory Medicine, 2013, 107, 656-664.	2.9	29
150	Sample sizes for clinical trials using sputum eosinophils as a primary outcome. European Respiratory Journal, 2013, 42, 1003-1011.	6.7	11
151	Sputum Hyaluronan and Versican in Severe Eosinophilic Asthma. International Archives of Allergy and Immunology, 2013, 161, 65-73.	2.1	32
152	Cytokine responses of peripheral blood mononuclear cells to allergen do not identify asthma or asthma phenotypes. Clinical and Experimental Allergy, 2013, 43, 1226-1235.	2.9	10
153	Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1177-1184.	5.7	78
154	Asthma Associated With Incontinentia Pigmenti and Fanconi Anemia. Chest, 2013, 143, 856-858.	0.8	1
155	Quantitative Sputum Cell Counts to Monitor Bronchitis: A Qualitative Study of Physician and Patient Perspectives. Canadian Respiratory Journal, 2013, 20, 47-51.	1.6	9
156	The Evolution of Sputum Cytometry to Assess Bronchitis. Canadian Respiratory Journal, 2013, 20, 415-416.	1.6	2
157	Update on Clinical Inflammometry for the Management of Airway Diseases. Canadian Respiratory Journal, 2013, 20, 117-120.	1.6	24
158	How to Diagnose and Phenotype Asthma. Clinics in Chest Medicine, 2012, 33, 445-457.	2.1	42
159	Serum periostin as a marker of TH2-dependent eosinophilic airway inflammation. Journal of Allergy and Clinical Immunology, 2012, 130, 655-656.	2.9	24
160	A sensitive high throughput ELISA for human eosinophil peroxidase: A specific assay to quantify eosinophil degranulation from patient-derived sources. Journal of Immunological Methods, 2012, 384, 10-20.	1.4	38
161	Cystic Fibrosis Transmembrane Conductance Regulator Gene Abnormalities in Patients with Asthma and Recurrent Neutrophilic Bronchitis. Canadian Respiratory Journal, 2012, 19, 46-48.	1.6	12
162	Safety and efficacy of a <scp>CXCR</scp>2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placeboâ€controlled clinical trial. Clinical and Experimental Allergy, 2012, 42, 1097-1103.	2.9	300

#	Article	IF	Citations
163	Reslizumab for Poorly Controlled, Eosinophilic Asthma. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1125-1132.	5.6	649
164	Expiratory flows and airway inflammation in elderly asthmatic patients. Respiratory Medicine, 2011, 105, 1284-1289.	2.9	37
165	Heterogeneity of Bronchitis in Airway Diseases in Tertiary Care Clinical Practice. Canadian Respiratory Journal, 2011, 18, 144-148.	1.6	62
166	Persistent Sputum Cellularity and Neutrophils May Predict Bronchiectasis. Canadian Respiratory Journal, 2011, 18, 221-224.	1.6	10
167	Frederick E Hargreave. Canadian Respiratory Journal, 2011, 18, 193-193.	1.6	0
168	Early interventions with inhaled corticosteroids in asthma: benefits and risks. Current Opinion in Pulmonary Medicine, 2011, 17, 12-15.	2.6	5
169	Reproducibility, Validity, and Responsiveness of Cell Counts in Blown Nasal Secretions. Allergy and Rhinology, 2011, 2, ar.2011.2.0006.	1.6	4
170	Serum Procalcitonin and Infective Exacerbations of Asthma. Chest, 2011, 140, 1389-1390.	0.8	1
171	Point: Is Measuring Sputum Eosinophils Useful in the Management of Severe Asthma? Yes. Chest, 2011, 139, 1270-1273.	0.8	27
172	The identification of eosinophilic gastroenteritis in prednisone-dependent eosinophilic bronchitis and asthma. Allergy, Asthma and Clinical Immunology, 2011, 7, 4.	2.0	8
173	Nontubercular Mycobacterial Pulmonary Infection in Severe Asthma. Chest, 2011, 139, 721.	0.8	0
174	Rebuttal From Drs Hargreave and Nair. Chest, 2011, 139, 1275-1277.	0.8	7
175	Measuring Bronchitis in Airway Diseases: Clinical Implementation and Application. Chest, 2010, 138, 38S-43S.	0.8	45
176	Monitoring sputum eosinophils in mucosal inflammation and remodelling: a pilot study. European Respiratory Journal, 2010, 35, 48-53.	6.7	18
177	Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma. Journal of Allergy and Clinical Immunology, 2010, 126, 404-406.	2.9	46
178	Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia. New England Journal of Medicine, 2009, 360, 985-993.	27.0	1,260
179	The definition and diagnosis of Asthma. Clinical and Experimental Allergy, 2009, 39, 1652-1658.	2.9	134
180	Antiinflammatory Effects of Long-Acting Î² 2 -Agonists in Patients With Asthma. Chest, 2009, 136, 145-154.	0.8	33

#	Article	IF	Citations
181	Clinical equivalence testing of inhaled bronchodilators. , 2009, 119, 731-5.		1
182	The Effects of Leptin on Airway Smooth Muscle Responses. American Journal of Respiratory Cell and Molecular Biology, 2008, 39, 475-481.	2.9	60
183	The Safety of Long-Acting Î²-Agonists among Patients with Asthma Using Inhaled Corticosteroids. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 1009-1016.	5.6	99
184	Asthma Management by Monitoring Sputum Neutrophil Count. Chest, 2008, 134, 628-630.	0.8	16
185	Cost Analysis of Monitoring Asthma Treatment using Sputum Cell Counts. Canadian Respiratory Journal, 2008, 15, 370-374.	1.6	17
186	Does early intervention with inhaled corticosteroids alter the natural history of mild persistent asthma?. , 2008, 118, 441-4.		0
187	Modulation of Human Airway Smooth Muscle Migration by Lipid Mediators and Th-2 Cytokines. American Journal of Respiratory Cell and Molecular Biology, 2007, 37, 240-247.	2.9	60
188	Ventilation and Perfusion Lung Scintigraphy of Allergen-Induced Airway Responses in Atopic Asthmatic Subjects. Canadian Respiratory Journal, 2007, 14, 285-291.	1.6	5
189	Altered Respiratory Physiology in Obesity. Canadian Respiratory Journal, 2006, 13, 203-210.	1.6	374
190	Treatment Strategy for Asthma. Chest, 2006, 129, 221-223.	0.8	4
191	Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. American Journal of Medicine, 2004, 116, 338-344.	1.5	225
192	Multiple lung nodules, eosinophilia and severe asthma. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 0, , 1-4.	0.5	0
193	Ventilation and perfusion abnormalities following recovery from noncritical COVID-19. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 0, , 1-10.	0.5	0